Seres Therapeutics has redesigned their SER-109 clinical study of a fecal transplant aiming to treat Clostridium difficile infection, which failed last July, and will re-initiate it, with FDA’s guidance.  Seres is the first publicly held microbiome-focused company, and, if approved, SER-109 would be the first approved microbiome therapeutic in this new field of medicine. (Industry Dive)